American Association for Cancer Research
ccr-22-2531_supplementary_table_s7_suppts7.docx (31.82 kB)

Supplementary Table S7 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)

Download (31.82 kB)
journal contribution
posted on 2023-04-01, 00:07 authored by Chaoyang Zhang, Fawaz N. Al-Shaheri, Mohamed Saiel Saeed Alhamdani, Andrea S. Bauer, Jörg D. Hoheisel, Miriam Schenk, Ulf Hinz, Philipp Goedecke, Karam Al-Halabi, Markus W. Büchler, Nathalia A. Giese, Thilo Hackert, Susanne Roth

List of extra miRNA classifiers.



Intraductal papillary mucinous neoplasm (IPMN) is a precursor of pancreatic ductal adenocarcinoma. Low-grade dysplasia has a relatively good prognosis, whereas high-grade dysplasia and IPMN invasive carcinoma require surgical intervention. However, diagnostic distinction is difficult. We aimed to identify biomarkers in peripheral blood for accurate discrimination. Sera were obtained from 302 patients with IPMNs and 88 healthy donors. For protein biomarkers, serum samples were analyzed on microarrays made of 2,977 antibodies. A support vector machine (SVM) algorithm was applied to define classifiers, which were validated on a separate sample set. For microRNA biomarkers, a PCR-based screen was performed for discovery. Biomarker candidates confirmed by quantitative PCR were used to train SVM classifiers, followed by validation in a different sample set. Finally, a combined SVM classifier was established entirely independent of the earlier analyses, again using different samples for training and validation. Panels of 26 proteins or seven microRNAs could distinguish high- and low-risk IPMN with an AUC value of 95% and 94%, respectively. Upon combination, a panel of five proteins and three miRNAs yielded an AUC of 97%. These values were much better than those obtained in the same patient cohort by using the guideline criteria for discrimination. In addition, accurate discrimination was achieved between other patient subgroups. Protein and microRNA biomarkers in blood allow precise diagnosis and risk stratification of IPMN cases, which should improve patient management and thus the prognosis of IPMN patients.

Usage metrics

    Clinical Cancer Research